‘Still keen to keep living': Eminent pathologist Professor Richard Scolyer reveals cancer has progressed
Professor Scolyer, 58, was diagnosed with the aggressive and incurable glioblastoma in 2023 and initially given just eight months to live. However, after undergoing experimental immunotherapy based on melanoma research, his cancer remained at bay for 18 months.
In a social media post on Monday, Professor Scolyer confirmed a recent MRI scan had shown further progression of the tumour on the left side of his brain.
'While this may not be the best direction to be heading with my changes, amazingly (to me), I still seem keen to keep living, loving and having fun, whenever possible,' he wrote on social media.
'I feel like there are quite a few people on my team (including my family & friends) and they make me happy and proud.'
The prominent cancer researcher, jointly named Australian of the Year in 2024 alongside fellow Melanoma Institute Australia co-director Professor Georgina Long, has remained remarkably candid and optimistic throughout his treatment journey.
In February, Professor Scolyer announced the cancer had returned, prompting him to undergo surgery in March to remove as much of the tumour as possible.
He later explained that while the procedure successfully removed a significant portion of the mass, 'little tentacles' remained and would require additional treatment to 'mop up' the remaining cancer cells.
'Depending on what the scan shows … that will help choose what are the next forms of therapy that I can have to see where we need to go from here,' he said at the time.
He also acknowledged the emotional and physical toll of ongoing treatment, admitting he had been feeling 'a little up and down' due to side effects, though he continued to cherish time spent with his wife Katie and their children.
'Sometimes I'm happy to have fun, but some of the therapies have knocked me around a bit, so I can't do some of the things I love doing,' he said.
'I'm still having a fun time at home with my kids, they've been very kind, as well as my beautiful wife Katie has, who's been using her incredible intellect to help me speak to different doctors about various options that are available.'
Professor Scolyer said he expects to undergo another operation and remains hopeful about future treatments.
'Fingers crossed this operation isn't so bad and we can move forward with the next form of therapy and hopefully push things along faster to try and get things open up for many, many patients who have got glioblastoma,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
‘Zoom in': Australian celebrities Lisa Wilkinson and Hamish Blake spoof viral ‘kiss cam' drama
A pair of Australian celebrities, Lisa Wilkinson and Hamish Blake, have hilariously spoofed the moment an American tech CEO was caught hugging a woman who was not his wife at a Coldplay concert. Wilkinson and Blake were in the audience for one of the stops on American stand-up comedian Nikki Glaser's tour of Australia. And all individuals involved apparently decided to have some fun. During her set, Glaser offered up her own version of the kiss cam that caught out Andy Byron, CEO of the company Astronomer, and Kristin Cabot, the business's chief people officer. 'Let's see if we have one more we can find. Can we zoom in?' Glaser asked as the camera focused on Blake and Wilkinson, who were pretending to be intimate. 'Is that ... is that ... is that Hamish and Lisa!? Oooooh, busted! Someone call Zoe right now. What the f***?' Blake is, of course, married to author and entrepreneur Zoe Foster Blake. Wilkinson is married to the former rugby player Peter FitzSimons. The clip of Mr Byron and Ms Cabot enjoying Coldplay's performance together, then ducking for cover upon being shown on the big screen, has gone viral this week. The scandal ended with Mr Byron resigning from his role at Astronomer. 'As stated previously, Astronomer is committed to the values and culture that have guided us since our founding,' the company said in a statement. 'Our leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met. 'Andy Byron has tendered his resignation, and the Board of Directors has accepted. The board will begin a search for our next Chief Executive.' Co-founder and Chief Product Officer Pete DeJoy is serving as interim CEO. The video of Mr Byron and Ms Cabot quickly went viral after being shared on TikTok. 'Either they're having an affair, or they're just very shy,' Coldplay's lead singer Chris Martin quipped to the crowd. 'Before this week, we were known as a pioneer in the DataOps space, helping data teams power everything from modern analytics to production AI,' Astronomer said. 'While awareness of our company may have changed overnight, our product and our work for our customers have not. 'We're continuing to do what we do best: helping our customers with their toughest data and AI problems.' Mr Byron's job reportedly paid him between $717,000 and a million dollars per year, plus performance-based bonuses.
SBS Australia
4 hours ago
- SBS Australia
Second case of rare mpox strain discovered in traveller
Listen to Australian and world news, and follow trending topics with SBS News Podcasts . "The patient has a close family, and that family are isolating at home. He was not contagious on the return journey to Australia from Africa, and those close contacts that he has been in contact including at the emergency ward and other locations are being contact traced right now and identified." That's Queensland's Health Minister Tim Nicholls, confirming a new strain of mpox virus has been detected in a man who's just returned to the south-east of the state from a trip to Africa. He says Mpox is a disease caused by the monkeypox virus. "Mpox is not easily spread. It is only spread or it can only spread through close or intimate contact. It is particularly spread by close sexual contact and particularly for gay men and people engaging with sex is the primary cause of the contagious spread." Dr Geoffrey Playford is the head of infectious diseases at the Princess Alexandra Hospital in Queensland. He says the rare Clade 1 strain of mpox has only been seen once before in Australia, also in a returned traveller. "Over the last year and a half in Queensland, we've had 135 cases in mpox clade 2 - this is the first case of clade 1 and the second time in Australia we've had clade 1. The other case was in New South Wales in May." Mr Nicholls says the public should NOT be concerned. "We think that there are 19 community contacts and 40 staff contacts that have been in contact with the patient. At the moment his symptoms are asymptomatic. They are not showing any signs of the clade 1 mpox, but they are isolating. The family involves children in high school, primary school and childcare centres and the high school, primary school and childcare centres either have been or are in the process of being identified." Dr Playford says authorities are not worried either. He says fortunately in this case the clinical presentation is relatively mild and there are no particular concerns for the patient's health. "And all of our efforts at the moment is to identify contacts using national guidelines to undertake quarantine where the very close contacts have been identified, again in line with the national guidelines." The close contacts will be offered a vaccine that is highly effective against mpox -either preventing or making the disease significantly milder and shorter. Mr Nicholls says over a year ago there were some restrictions on the availability of the vaccine. But now, Queensland has ample supplies - and the vaccine is provided free of charge through sexual health clinics and some GPs [[general practitioners]]. The Queensland government is advising anyone who suspects they may have the virus to seek medical advice from their local doctor, sexual health clinic or public health unit.
SBS Australia
6 hours ago
- SBS Australia
How some Aussies are tackling the 'massive hurdles' of ADHD diagnosis and treatment
When Zac Altman returned to Australia, he didn't expect that a frustrating journey trying to get rediagnosed with ADHD would propel him to start a business seeking to address the flaws of the system. Altman is the founder of Kantoko, a telehealth platform that offers ADHD assessment and care under a subscription model. After being diagnosed with ADHD while living in the United States, he returned home — and found he needed to start his diagnosis journey from scratch. "I was already diagnosed, already on the medication, had the documentation. I thought it was going to be pretty straightforward. And for me, it was a challenge," he told SBS News. "I don't think I ever would've made it through the process if I were starting in Australia from the get-go because of the massive hurdles and burdens required with getting through the process." Altman's struggles reflect a broader issue when it comes to the diagnosis and treatment of ADHD in Australia: despite rising awareness and demand, the system is still playing catch-up — and some states are lagging behind. Zac Altman says he would never have founded his ADHD telehealth business if he hadn't struggled with the diagnosis process himself. Source: Supplied A postcode lottery All states and territories have different laws governing how stimulant medications — commonly prescribed to treat ADHD — can be prescribed and dispensed. In some places, the process is more streamlined. In others, patients face stricter regulatory barriers — often accompanied by longer wait times and higher costs. Dr Roger Paterson, a psychiatrist based in Western Australia, said there was "always a postcode privilege for all levels of healthcare". "ADHD treatment is no different," he told SBS News. He said ADHD diagnosis and treatment rates have surged in Australia — but not uniformly. "We're still below the prevalence rates … but some states and territories have caught up quicker than others." Paterson told SBS News. Patterson said South Australia, Tasmania, Victoria and the Northern Territory remain the slowest to catch up, while Western Australia — which once lagged behind — has now reached similar levels to Queensland. "No-one really knows why [some states lag], beyond the NT not having many specialists — paediatricians or psychiatrists. But they are all gradually catching up to the ADHD prevalence rates." Prevalence refers to the proportion of a population that is affected by ADHD. While there are no Australian adult prevalence studies of ADHD using the current DSM-5 diagnostic criteria, some studies have indicated the prevalence of ADHD in Australia is likely to be similar to that found internationally — between 2 and 6 per cent of the population, according to the Australasian ADHD Professionals Association. Rates of prescribing vary across states and territories, reflecting the different jurisdictional laws about stimulant prescribing. Source: SBS News Additionally, the federal government's Drug Utilisation Sub Committee September 2023 report found differences in the rates of prescribing across states and territories, which the report says reflects different laws across jurisdictions. Adult rates of prescribing were significantly higher in Western Australia and the ACT compared to the other states and the Northern Territory. The federal Senate inquiry into ADHD, handed down in November 2023, examined the barriers to consistent, timely and best-practice assessment of ADHD. It heard those living in regional and rural areas were subject to even more barriers to care, with reduced access to specialists, longer wait times and higher costs. Altman said the differences were most pronounced in Kantoko clients moving interstate who had to navigate different jurisdictional regulations, sometimes requiring them to find an entirely new specialist. "It seems somewhat unreasonable to expect every psychiatrist to know every quirk across the country ... which is why I would argue we should have some sort of national standard around this stuff," he said. A patchwork system with no national rules Altman said going through the assessment process in Australia can feel like "a roll of the dice" due to a lack of national rules. He said he paid about $1,500 out of pocket to be rediagnosed in his first year back in Australia — including an upfront $1,000 fee to secure a psychiatrist appointment in NSW. He said he was fortunate to have leftover medication from the US to tide him over in the months he waited, but he knows others aren't so lucky. "It's the luck of the draw," he said. The inquiry heard that of those who did have positive experiences of ADHD assessment and diagnosis, "many attributed their experience to luck" or to doctors and psychiatrists who helped them access services. There is no national framework for ADHD, despite it being a key recommendation in the inquiry. The inquiry heard wait times were found to be "significant", typically between six and 18 months for an initial appointment, while the Australian Association of Psychologists Inc said the number of mental health professionals has not kept up with the demand for services. The public system rarely treats the condition except in children, pushing adults seeking a diagnosis to the private sector. As specialists set their own fees with no cap, people can be subject to high fees. The ADHD Foundation said it had observed some professionals charge up to $5,000 for assessments. 'Kantoko wouldn't exist if Australia nailed it' In response, ADHD telehealth services like Kantoko have cropped up. Operating completely online, these clinics promise shorter wait times — but sometimes at a greater cost. Kantoko operates under a subscription model. Medicare does not cover any fees. In exchange, patients are promised an ADHD assessment by a qualified psychiatrist, follow-up appointments with mental health doctors and prescription renewals. "Kantoko wouldn't exist if Australia had nailed it," Altman said. "I wouldn't have gotten so frustrated that I started this business and embarked on this journey if it were easy-to-access and affordable." But the Senate inquiry heard concerns about the growing telehealth service model, saying that while it was helpful for those in regional areas, it has also driven up risks associated with "inadequate assessment and misdiagnosis", according to the Australian College of Mental Health Nurses. The Canberra and Queanbeyan ADHD Support Group, a volunteer-run local group, said the clinics offered "exceedingly high fees delivering a quick turnaround" with concerns of "price gouging". The GP debate: solving shortages or lowering the bar? As the system plays catch-up, a key recommendation from the inquiry was the development of uniform and nationally consistent ADHD prescribing rules — the only recommendation of the 15 that the government accepted in full. But the government said the establishment of prescribing arrangements, including increased GP involvement, was a matter for state and territory governments. NSW, ACT, SA and WA have committed to reforms that will allow specially trained GPs to prescribe ADHD medication independently from 2025 and 2026. They'll join jurisdictions like Queensland, where GPs have been able to prescribe certain ADHD medications for children without prior approval since 2017. While some say it could ease bottlenecks and encourage holistic care, others warn it risks lowering the standards of care. Paterson said the current model is for specialists to handle diagnosis and stabilisation, before shifting to a shared care arrangement with GPs — known as co-prescribing. He's sceptical of political moves to shift ADHD treatment onto GPs in an effort to play catch-up. "Some GPs have pushed for taking on initial, independent assessment and prescribing, and politicians push this along as a popular way of reducing waiting lists," Paterson said. "This creates a tension between reducing waitlists with more GP involvement on the one hand, but on the other hand, accepting that GP ADHD management may not have the nuance of specialist management." There are concerns that relaxing GP restrictions could open the door to so-called 'dexy clinics' — where stimulant medications such as dexamphetamines might be handed out too freely, similar to concerns seen with medicinal cannabis. "There would be less concern about lower GP numbers who are highly trained, and more concern about higher GP numbers who are less trained," Paterson said. "The worst case scenario is that stimulant medication becomes as accessible as cannabis from the medicinal cannabis clinics." But Dr Alison Poulton, a senior lecturer in paediatrics at The University of Sydney and member of ADHD Australia's advisory board, pushed back against 'dexy clinic' fears, saying that ongoing relationships between GPs and patients would reduce risk and encourage more holistic care. She criticised current restrictions requiring specialist endorsement and fixed dosage limits, arguing they undermine both patient autonomy and the ability of GPs to tailor care. "It makes complete nonsense of patient autonomy," she said. "Decisions should be made between the GP and patient, not based on a letter written five years ago." Poulton emphasised that GPs, who often have a long-term understanding of their patients, are well placed to make prescribing decisions that reflect changing needs, leading to better functional outcomes. "I think the GPs are going to do a much better job if they know it's up to them to make these prescribing decisions rather than to have to consult the specialist."
